Skip to main content
. 2022 Jan 12;17(1):e0262267. doi: 10.1371/journal.pone.0262267

Fig 4. The cumulative rates of HCC development by etiology and hyaluronic acid.

Fig 4

(a) between cirrhosis and non-cirrhosis, (b) between HA ≥75 ng/mL and <75 ng/mL. HCC, hepatocellular carcinoma; DAA, direct-acting antiviral; LC, liver cirrhosis; HA, hyaluronic acid.